Last reviewed · How we verify
Guideline treatment with parenteral antibiotics
Guideline treatment with parenteral antibiotics is a Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved.
Guideline treatment with parenteral antibiotics, marketed by Rigshospitalet in Denmark, holds a significant position in the clinical management of bacterial infections. The key composition patent, set to expire in 2028, provides a strong barrier to generic competition, maintaining the drug's market exclusivity. The primary risk lies in the potential for new entrants to challenge the market post-patent expiry, which could erode revenue and market share.
At a glance
| Generic name | Guideline treatment with parenteral antibiotics |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (PHASE2)
- Partial Oral Treatment of Endocarditis (PHASE4)
- Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis (NA)
- Operational Research Management for Children With Severe Pneumonia (NA)
- Clinical Trials to Reduce the Risk of Antimicrobial Resistance (PHASE2)
- Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin (PHASE3)
- Ethanol Lock for the Salvage of Infected Long-term Vascular Access (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guideline treatment with parenteral antibiotics CI brief — competitive landscape report
- Guideline treatment with parenteral antibiotics updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI